Health · Medical Research · 3 hrs ago
Pine bark extract linked to lower pain scores in women with low bone density
A trial tested French maritime pine bark extract in women with osteopenia or osteoporosis, conditions that reduce bone density and can raise fracture risk.
The single-center study enrolled 67 women with low bone density and compared the supplement with a placebo for the first three months.
Participants then entered a three-month extension in which everyone received the extract.
Women taking the extract reported better bodily pain scores, and vitality scores were also assessed.
These quality-of-life measures were secondary or exploratory outcomes, so the trial was not designed to provide a definitive test of the supplement’s effect on pain.
The study also monitored health and safety measures, but its findings do not establish that the extract prevents fractures or replaces standard osteoporosis treatment.
A six-month clinical trial linked French maritime pine bark extract with lower pain scores among women with low bone density.
The study evaluated Pycnogenol® supplementation in women with osteopenia or stable osteoporosis.
The single-center, randomized, double-blind, placebo-controlled trial enrolled 67 women.
Participants initially received Pycnogenol® or a placebo for three months, followed by three months in which all participants received the extract.
The researchers also assessed quality of life, vitality and safety.
- Who
- 67 women with osteopenia or osteoporosis took part.
- What
- Researchers studied the effects of French maritime pine bark extract, sold as Pycnogenol®, on pain, quality of life, vitality and safety.
- When
- Participants were enrolled between October 2021 and January 2024 and followed for six months.
- Where
- The study was conducted at a single center; its location is not stated.
- Why
- Researchers investigated whether the extract could affect pain, quality of life, vitality and safety in women with low bone density.
This story does not have two clearly opposing sides.
Researchers enrolled participants in the trial.
Participants received Pycnogenol® or a matching placebo.
All participants received Pycnogenol®.
News-Medical published its report on the study.
- Participants
- 67 women
- Initial Pycnogenol® group
- 33 participants
- Initial placebo group
- 34 participants
- Extract dose
- 100 mg twice daily
- Trial duration
- Six months